Ben Derman

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Ben Derman
Dec 19, 2024, 15:56 | Science
HBI0101 BCMA-directed CAR-T experience in AL amyloid, summarised by Ben Derman
Ben Derman, Assistant Professor at University of Chicago, shared an article by Eyal Lebel on…
Dec 11, 2024, 19:11 | Drugs
Results of AQUILA Trial: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for treating multiple myeloma. On December 9th…
Dec 1, 2024, 22:10 | Opinion
Mike Thompson: Myeloma/Plasma Cell Dyscrasia Draft Table Update
Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, posted the following on X:…
Jul 14, 2024, 02:56 | Drugs
Belamaf-based triplet regimens are effective in patients with R/R multiple myeloma - ASCO
ASCO shared on X: "The DREAMM-7 and DREAMM-8 studies established the effectiveness of belamaf-based triplet…
Jun 12, 2024, 05:15 | Blog
Brand new episode on updates in Myeloma MRD - Blood Cancer Talks
Ben Derman, Assistant Professor at the University of Chicago, recently shared a post by Blood…
May 31, 2024, 09:24 | Insight
Vincent Rajkumar: International Myeloma Working Group guidelines CAR-T cell treatment in myeloma by Yi Lin
Vincent Rajkumar shared on X: "Just out: International Myeloma Working Group guidelines CAR-T cell treatment…
Apr 18, 2024, 13:58 | Insight
Ben Derman: Should MRD negativity be accepted as a surrogate endpoint for clinical trials in myeloma
Ben Derman, Assistant Professor at the University of Chicago, shared on X/Twitter: "Should MRD negativity…
Aug 16, 2023, 19:07 | Drugs
Ben Derman: Some thoughts on Elrantamab in light of approval.
Dr. Ben Derman, Assistant Professor at the University of Chicago, recently shared in a Twitter…
All: 8 Posts: 1 - 100
Special Coverage